Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.46 USD | -2.60% | -3.72% | -14.80% |
05-20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
05-14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.80% | 6.12B | |
+10.69% | 115B | |
+11.78% | 106B | |
-6.02% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.35% | 17.56B | |
-40.50% | 17.32B | |
+6.13% | 14.03B | |
+31.42% | 12.13B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Investor Farallon Capital Plans to Nominate Three New Independent Directors to Board, Cites Strategy Concerns